Global Human Immunodeficiency Virus Testing Market Size By Type (Antibody Tests, RNA (viral load) Test), By Application (Diagnostic Centers, Hospitals), By Region, And Segment Forecasts, 2023 to 2032

The Global Human Immunodeficiency Virus (HIV) Testing Market was valued at USD 5.7 billion in 2023 and is projected to surpass USD 9.4 billion by 2031, registering a CAGR of 6.5% during the forecast period from 2023 to 2031. The market growth is driven by the rising prevalence of HIV infections, increasing awareness regarding early detection, and advancements in diagnostic technologies. With improved accessibility to HIV testing services in both developed and developing regions, the demand for rapid and highly accurate testing solutions continues to grow.

Government initiatives, healthcare programs, and collaborations with non-profit organizations are further supporting the expansion of HIV testing services. Additionally, self-testing kits and point-of-care (POC) testing solutions are gaining traction, making HIV testing more accessible and efficient.

Drivers

Rising Prevalence of HIV and Increasing Awareness

The increasing number of HIV-infected individuals globally is a significant driver of the market. According to UNAIDS, around 39 million people were living with HIV by the end of 2022, with a substantial number still undiagnosed. Governments and health organizations are actively promoting early diagnosis and treatment, thereby boosting the demand for HIV testing services.

Advancements in Diagnostic Technologies

Technological innovations in HIV diagnostics, such as rapid antigen/antibody tests, nucleic acid amplification tests (NAATs), and point-of-care (POC) testing devices, are enhancing test accuracy, speed, and accessibility. The integration of AI-powered diagnostics and mobile health (mHealth) applications is also improving real-time monitoring and screening.

Government and NGO Initiatives

Several governments and non-governmental organizations (NGOs) are implementing HIV testing and awareness programs to encourage early detection and treatment adherence. Global initiatives such as the UNAIDS 95-95-95 targets (ensuring 95% of people with HIV know their status, 95% receive treatment, and 95% achieve viral suppression) are significantly contributing to market growth.

Restraints

Social Stigma and Discrimination

Despite increasing awareness, social stigma, discrimination, and fear of positive HIV diagnosis deter individuals from getting tested. This challenge is particularly significant in developing and underdeveloped nations, where cultural barriers often prevent people from seeking timely medical intervention.

High Cost of Advanced HIV Testing

While traditional HIV tests are relatively affordable, advanced diagnostic methods such as NAAT and fourth-generation antigen/antibody tests can be expensive, especially in low-income and middle-income countries. Limited healthcare budgets and insufficient funding may hinder the widespread adoption of advanced HIV testing solutions.

Opportunity

Expansion of Self-Testing Kits and Home-Based Testing

The growing adoption of HIV self-testing (HIVST) kits is creating significant opportunities in the market. Self-testing offers privacy, convenience, and ease of use, making it an effective solution for reaching underserved populations. Regulatory approvals for self-testing kits and partnerships between health agencies and diagnostic companies are accelerating the market growth.

Emerging Markets in Asia-Pacific and Africa

Developing regions, particularly Asia-Pacific and Sub-Saharan Africa, present lucrative opportunities for market players due to the high HIV burden, increasing healthcare investments, and growing awareness programs. Strengthening healthcare infrastructure in these regions is expected to drive substantial market expansion.

Market by Test Type Insights

Based on test type, the Antibody Test segment accounted for the largest market share in 2023. Antibody tests, particularly enzyme-linked immunosorbent assays (ELISA) and rapid diagnostic tests (RDTs), are widely used due to their cost-effectiveness, high accuracy, and easy accessibility.

However, the Nucleic Acid Amplification Test (NAAT) segment is projected to witness the fastest growth during the forecast period. NAATs provide early HIV detection by identifying the virus at very low levels in the blood, making them highly effective for early-stage diagnosis.

Market by End-Use Insights

Based on end-use, the Diagnostic Laboratories segment emerged as the largest revenue contributor in 2023. Laboratories remain the primary testing centers for large-scale HIV screening due to their ability to process high volumes of tests with high precision.

However, the Home-Based Testing segment is expected to exhibit the highest growth rate, driven by the increasing availability of self-testing kits and rising consumer preference for confidential and convenient testing options.

Market by Regional Insights

North America

North America held the largest market share in 2023, driven by high awareness, strong government support, and advanced healthcare infrastructure. The United States, in particular, has a robust HIV surveillance and testing framework, contributing to the market’s dominance.

Europe

Europe ranks second, supported by government-funded HIV testing programs and favorable healthcare policies. Countries like Germany, France, and the UK are leading in the adoption of rapid HIV diagnostics and self-testing kits.

Asia-Pacific

Asia-Pacific is anticipated to register the highest CAGR during the forecast period. Countries such as India, China, and Thailand are increasing efforts to expand access to HIV testing and improve early diagnosis rates.

Sub-Saharan Africa

While Sub-Saharan Africa remains the region with the highest HIV burden, increasing international funding and collaborations with NGOs are driving market growth. Efforts by organizations like UNAIDS, WHO, and PEPFAR are enhancing HIV screening and prevention programs.

Competitive Scenario

Key players in the Global HIV Testing Market include:

Abbott Laboratories

Bio-Rad Laboratories

F. Hoffmann-La Roche Ltd.

Siemens Healthineers

OraSure Technologies, Inc.

Chembio Diagnostic Systems, Inc.

bioMérieux SA

Hologic, Inc.

Trinity Biotech

BD (Becton, Dickinson and Company)

These companies focus on product innovations, strategic partnerships, and geographical expansion to strengthen their market presence. Recent advancements include the launch of rapid antigen/antibody test kits, AI-integrated diagnostics, and mobile HIV testing solutions.

Scope of Work – Global Human Immunodeficiency Virus (HIV) Testing Market

Key Market Developments

November 2023: Abbott Laboratories launched a next-generation rapid HIV antigen/antibody test designed for early-stage HIV detection.

July 2023: OraSure Technologies received FDA approval for its new self-testing HIV kit, allowing wider accessibility for at-home testing.

April 2023: Siemens Healthineers partnered with leading healthcare institutions to implement AI-based HIV screening tools in diagnostic laboratories.

March 2023: Roche Diagnostics expanded its HIV testing portfolio by integrating automated workflow solutions for large-scale laboratory testing.

Frequently Asked Questions (FAQs)

1. What is the current market size of the Global HIV Testing Market?

The market was valued at USD 5.7 billion in 2023 and is projected to grow significantly by 2031.

2. What is the major growth driver of the HIV Testing Market?

The market is driven by the rising prevalence of HIV infections, increasing awareness, and advancements in diagnostic technologies.

3. Which is the largest region during the forecast period in the HIV Testing Market?

North America is expected to remain the largest market due to strong healthcare infrastructure and widespread testing initiatives.

4. Which segment accounted for the largest market share in the HIV Testing Market?

The Antibody Test segment led the market in 2023, owing to its cost-effectiveness and high accuracy.

5. Who are the key market players in the HIV Testing Market?

Leading companies include Abbott, Roche, Siemens Healthineers, BD, Bio-Rad Laboratories, and OraSure Technologies.